Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

OXFORD, United Kingdom, June 12, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of... | June 12, 2023

Related Keywords

Italy ,United Kingdom ,Cappuccini ,Cumbria ,United States ,Spain ,American ,Meg Marshall ,J Clin Onc ,University Of Oxford ,Astrazeneca ,Exchange Commission ,Nasdaq ,Bill Enright ,Chief Executive Officer ,Chief Medical Officer ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Urol Int ,Prostate Cancer ,Cancer United Kingdom ,About Prostate Cancer ,Hopkins Medicine ,Prostate Cancer Prognosis ,